Was UKPDS 34 a double-blind trial?

No. UKPDS 34 was open-label. Patients, clinicians, and study staff knew which treatment arm each participant was assigned to. Endpoint adjudication was performed centrally to reduce assessment bias, but performance bias from differential clinical attention cannot be excluded.

How was the primary endpoint defined in UKPDS 34?

The primary endpoint was "any first diabetes-related clinical endpoint," a composite of 21 events including sudden death, death from hyperglycemia or hypoglycemia, fatal or non-fatal MI, angina, heart failure, stroke, renal failure, amputation, vitreous hemorrhage, retinal photocoagulation, blindness, and cataract extraction.

Why was UKPDS 34 run separately from UKPDS 33?

Metformin was tested only in overweight patients (>120% ideal body weight) because its insulin-sensitizing mechanism was hypothesized to work differently in this population. The overweight stratum was pre-specified in the original protocol as a distinct randomization tier.

What was the comparator in UKPDS 34?

The primary comparator was conventional therapy with dietary management alone. A secondary comparison involved patients randomized to sulfonylurea-based or insulin-based intensive therapy. No patient received a placebo tablet.

Did metformin reduce microvascular complications in UKPDS 34?

The point estimate for microvascular risk reduction was 29%, but this did not reach statistical significance (p = 0.19). The composite result was driven primarily by reductions in myocardial infarction and all-cause mortality.

What is the 'legacy effect' from the UKPDS post-trial follow-up?

After the trial ended, HbA1c levels converged between groups within one year. Despite this, patients originally assigned to metformin continued to show significant reductions in MI and all-cause mortality 10 years later. This persistent benefit after glycemic convergence is termed the "legacy effect."

Did UKPDS 34 raise safety concerns about metformin-sulfonylurea combinations?

A secondary analysis showed a 96% increase in diabetes-related mortality when metformin was added to sulfonylurea therapy (p = 0.039). This finding was not replicated in the 10-year post-trial follow-up or in subsequent studies, and the authors urged caution in interpreting the result due to small sample size and lack of multiplicity adjustment.

How generalizable is UKPDS 34 to today's type 2 diabetes patients?

Limited in several ways. The cohort was predominantly White British, excluded patients with established cardiovascular disease, and used a dietary-only comparator that no longer reflects standard of care. Modern patients typically receive concurrent SGLT2 inhibitors, GLP-1 RAs, statins, and antihypertensives.

Did UKPDS 34 use hazard ratios or Cox regression?

The primary analysis used log-rank tests and reported relative risk reductions. Cox proportional hazards models with covariate adjustment were not presented in the original paper. Later re-analyses by the UKPDS group confirmed the findings using multivariable Cox models.

Why does UKPDS 34 still matter if the comparator is outdated?

It remains the only large RCT demonstrating hard cardiovascular endpoint reduction with metformin in type 2 diabetes. No subsequent trial has replicated this head-to-head against modern comparators, which is why guidelines still reference it as foundational evidence for metformin's first-line status.

Inside the UKPDS 34 Methodology: What Most Summaries Skip

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

| Field | Detail | |---|---| | Trial | UKPDS 34 (United Kingdom Prospective Diabetes Study, metformin sub-study) | | N | 1,704 (753 metformin, 951 conventional) | | Intervention | Metformin, titrated to maximum tolerated dose | | Comparator | Conventional dietary therapy (primary); secondary comparisons to sulfonylurea/insulin | | Duration | Median follow-up 10.7 years | | Primary endpoint | Any first diabetes-related clinical endpoint (composite) | | Key result | 32% risk reduction vs. conventional (p = 0.002) | | Publication | Lancet 1998; 352: 854-865 |

Why a Separate Sub-Study?

The main UKPDS (study 33) enrolled 3,867 patients across all BMI categories and randomized them to intensive glucose control with sulfonylureas or insulin versus conventional diet-based management. UKPDS 34 was a pre-specified parallel study restricted to overweight patients (defined as >120% ideal body weight). The rationale: metformin's mechanism of action, primarily hepatic glucose output suppression without stimulating insulin secretion, suggested it might perform differently in patients with higher insulin resistance. This was not a post-hoc subgroup analysis. The protocol specified the overweight stratum as a distinct randomization tier from the outset, giving the metformin comparison independent statistical standing.

Randomization and Allocation

The Stratification Scheme

Patients were stratified by study center (23 UK hospital clinics) and then randomized in a ratio of approximately 3:1 within the overweight group: 753 to metformin-based intensive therapy and 951 to conventional (diet-only) management. An additional 342 overweight patients were randomized to sulfonylurea or insulin-based intensive arms for secondary comparison.

A critical design feature: allocation was not blinded. UKPDS 34 was an open-label trial. Patients, clinicians, and clinic staff knew which arm each participant occupied. This matters because unblinded assignment introduces performance bias. Clinicians managing patients in the intensive arm may have pursued tighter glucose targets more aggressively, offered more lifestyle counseling, or monitored cardiovascular risk factors more closely. The study attempted to mitigate this through standardized clinic protocols and centralized endpoint adjudication, but an open-label design cannot fully eliminate differential co-intervention.

No Placebo Arm

The conventional-therapy arm received dietary advice alone. There was no placebo tablet. This means the comparison captured the combined effect of metformin pharmacology plus the behavioral effects of taking a daily medication (adherence attention, clinic visit structure for dose titration). For a 10-year study, these non-pharmacological effects are likely small relative to the drug's metabolic action, but they are not zero.

Interpreting the Primary Endpoint: A Composite by Design

The primary outcome, "any first diabetes-related endpoint," was a composite of 21 distinct clinical events spanning microvascular disease (retinopathy requiring photocoagulation, vitreous hemorrhage, renal failure), macrovascular disease (myocardial infarction, stroke, peripheral vascular disease), and metabolic emergencies (fatal or non-fatal hyperglycemia/hypoglycemia). The full list appears in the companion UKPDS 33 methods paper.

Why Composites Can Mislead

Composite endpoints increase statistical power by pooling events, but they weight a fatal MI and a single session of retinal photocoagulation equally. The 32% risk reduction applies to the first occurrence of any event in the basket. It does not mean that every component dropped by 32%. The individual-component results tell a more specific story:

| Endpoint | Risk Reduction vs. Conventional | p-value | |---|---|---| | Any diabetes-related endpoint | 32% | 0.002 | | Diabetes-related death | 42% | 0.017 | | All-cause mortality | 36% | 0.011 | | Myocardial infarction | 39% | 0.01 | | Stroke | 41% | 0.13 (NS) | | Microvascular endpoints | 29% | 0.19 (NS) |

The stroke and microvascular reductions were not statistically significant. The mortality and MI reductions drove the composite. This distinction matters clinically: metformin's proven benefit in this trial is primarily macrovascular and mortality-related, not microvascular. The ADA Standards of Care reflect this by recommending metformin for cardiovascular risk reduction rather than for retinopathy or nephropathy prevention specifically.

Statistical Approach and the Estimand Question

Intention-to-Treat with Long Crossover Exposure

UKPDS 34 used intention-to-treat (ITT) analysis. Patients were analyzed according to their original randomization assignment regardless of subsequent therapy changes. Over a median 10.7-year follow-up, substantial crossover occurred. Many patients in the conventional arm eventually required pharmacotherapy as their disease progressed, and some metformin patients switched to or added sulfonylureas or insulin.

The ITT approach answers the question: "What happens when you start with metformin-based intensive therapy versus starting with diet alone?" It does not answer: "What is the effect of being on metformin right now?" This is the estimand distinction that modern trial design (ICH E9 R1 addendum) would require investigators to pre-specify. In 1998, the framework did not exist, but the choice shapes interpretation. The 32% reduction is a policy-level estimate (start metformin early) rather than a pharmacological-exposure estimate.

Multiplicity and the Secondary Comparison Problem

The trial report includes a secondary comparison that created lasting confusion. When metformin was compared to sulfonylurea/insulin-based intensive therapy (not to conventional therapy), a combined analysis of metformin-plus-sulfonylurea showed a 96% increase in diabetes-related mortality (p = 0.039). This finding contradicted the primary result and generated a decade of clinical uncertainty about metformin-sulfonylurea combinations.

The investigators noted that this secondary analysis involved a smaller sample (537 patients) and multiple comparisons without formal multiplicity adjustment. Subsequent analyses, including the UKPDS 10-year post-trial follow-up published in 2008, showed that the sulfonylurea-combination signal did not persist. The mortality benefit of early metformin assignment, however, continued to separate from the conventional arm even after the trial ended, a phenomenon the authors termed a "legacy effect."

No Hazard Ratios in the Original Report

UKPDS 34 reported relative risk reductions and used log-rank tests for time-to-event comparisons. The paper did not present Cox proportional hazards models with covariate adjustment for the primary analysis. Unadjusted comparisons in a randomized trial are valid if randomization was successful, but the open-label design and 10-year follow-up window (during which BMI, blood pressure medications, and smoking status changed differentially) leave room for residual confounding that covariate adjustment could have addressed. Later re-analyses by the UKPDS group did apply Cox models and confirmed the primary finding.

Inclusion, Exclusion, and Generalizability

Who Got In

Eligible patients had newly diagnosed type 2 diabetes (fasting plasma glucose >6.0 mmol/L on two occasions after three months of dietary run-in) and were overweight (>120% ideal body weight by Metropolitan Life tables, roughly equivalent to BMI >25 in most patients). The age range was 25 to 65 at enrollment. Patients with recent MI, angina, heart failure, or more than one major vascular event were excluded.

Who Was Missing

The trial enrolled patients in the 1970s and 1980s across UK centers. The cohort was predominantly White British. Representation of South Asian, Black, and other ethnic groups, populations with substantially different type 2 diabetes prevalence and phenotype, was minimal. The FDA label for metformin cites UKPDS broadly but does not restrict the indication by ethnicity; the generalizability gap remains an acknowledged limitation rather than a contraindication.

Patients with established cardiovascular disease were excluded, which means UKPDS 34 cannot directly inform metformin's role in secondary cardiovascular prevention. Later trials and meta-analyses, including the 2020 Cochrane review on metformin monotherapy, have noted that evidence for metformin's cardiovascular benefit outside the UKPDS overweight cohort remains surprisingly thin.

The Comparator Problem in 2026

UKPDS 34 compared metformin to dietary therapy alone. No patient in the comparator arm received an SGLT2 inhibitor, GLP-1 receptor agonist, or even an ACE inhibitor as standard background therapy. The standard of care for a newly diagnosed overweight patient with type 2 diabetes in 2026 looks nothing like the conventional arm of UKPDS 34.

This does not invalidate the trial. It means the effect size (32% relative risk reduction) describes metformin versus a comparator that no longer exists in clinical practice. The absolute risk reduction and number needed to treat are specific to a population managed without modern cardiovascular-protective co-therapies. When the 2022 ADA/EASD consensus report positions metformin alongside SGLT2 inhibitors and GLP-1 RAs as first-line options, it is extrapolating from UKPDS 34's relative signal into a treatment environment the trial never tested.

Follow-Up Data: The Legacy Effect

The UKPDS post-trial monitoring study (Holman et al., NEJM 2008) followed surviving participants for an additional 10 years after the trial ended. During post-trial follow-up, HbA1c differences between the original randomization groups converged within one year. Yet the metformin group continued to show significant reductions in MI risk (33%, p = 0.005) and all-cause mortality (27%, p = 0.002).

This "legacy effect" suggests that early intensive glucose control with metformin confers durable cardiovascular protection that persists beyond the period of glycemic separation. The biological mechanism remains debated: epigenetic vascular changes, early plaque stabilization, or simply delaying the onset of the first event (which then shifts the entire survival curve) have all been proposed.

Limitations the Authors Acknowledged

The original publication listed several limitations directly:

Open-label design with potential for performance bias
Multiple secondary comparisons without formal multiplicity correction
The unexpected sulfonylurea-combination mortality signal, which the authors called "unexplained" and urged caution in interpreting
Relatively small sample size for the metformin-vs-intensive comparison (753 vs. 951 for the primary analysis, but only 537 for the combination sub-analysis)
Inability to distinguish metformin's glucose-lowering effect from potential non-glycemic mechanisms (anti-inflammatory, AMPK activation, weight neutrality)

What This Means for Clinical Practice

UKPDS 34 remains the single most cited justification for metformin as first-line therapy in type 2 diabetes. Its strengths are real: long follow-up, hard clinical endpoints, pre-specified overweight stratification, and a durable legacy effect confirmed a decade later. Its limitations are equally real: open-label design, composite endpoint driven by macrovascular events, an outdated comparator, and a cohort that does not reflect modern demographic diversity.

Clinicians citing the "32% reduction" should specify: 32% reduction in a composite of 21 diabetes-related endpoints, versus diet alone, in predominantly White British overweight patients diagnosed in the 1980s, analyzed by intention-to-treat over 10.7 years. That sentence is less quotable. It is also more honest.

Frequently asked questions

›

References

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865. PubMed
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589. PubMed
Metformin hydrochloride prescribing information. U.S. Food and Drug Administration. FDA Label
Boussageon R, Supper I, Bejan-Angoulvant T, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. Cochrane Database Syst Rev. 2020. PubMed
Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the ADA and EASD. Diabetologia. 2022;65(12):1925-1966. PubMed